Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) Invested Capital (2016 - 2026)

OptimizeRx's Invested Capital history spans 16 years, with the latest figure at $154.6 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 2.18% to $154.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $154.6 million, a 2.18% increase, with the full-year FY2025 number at $154.6 million, up 2.18% from a year prior.
  • Invested Capital hit $154.6 million in Q4 2025 for OptimizeRx, up from $151.1 million in the prior quarter.
  • Over the last five years, Invested Capital for OPRX hit a ceiling of $164.8 million in Q4 2023 and a floor of $115.8 million in Q2 2023.
  • Historically, Invested Capital has averaged $133.8 million across 5 years, with a median of $128.2 million in 2021.
  • Biggest five-year swings in Invested Capital: skyrocketed 186.59% in 2021 and later decreased 17.76% in 2023.
  • Tracing OPRX's Invested Capital over 5 years: stood at $131.4 million in 2021, then decreased by 4.01% to $126.1 million in 2022, then soared by 30.71% to $164.8 million in 2023, then fell by 8.22% to $151.3 million in 2024, then rose by 2.18% to $154.6 million in 2025.
  • Business Quant data shows Invested Capital for OPRX at $154.6 million in Q4 2025, $151.1 million in Q3 2025, and $148.6 million in Q2 2025.